# PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

> **NCT06069830** · NA · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 89 (estimated)

## Conditions studied

- NK-T-Cell Lymphoma, Extranodal

## Interventions

- **DRUG:** 4 cycles of ESA regimen with sandwiched radiotherapy
- **DRUG:** 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
- **DRUG:** 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase

## Key facts

- **NCT ID:** NCT06069830
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06069830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06069830, "PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06069830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*